Ratings Fresenius Medical Care AG

Equities

FME

DE0005785802

Market Closed - Xetra 11:41:19 2024-04-15 am EDT After market 03:26:14 pm
35.4 EUR -0.11% Intraday chart for Fresenius Medical Care AG 35.24 -0.45%

Summary

  • The company has a good ESG score relative to its sector, according to Refinitiv.

Strengths

  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

  • With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
  • The group shows a rather high level of debt in proportion to its EBITDA.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Healthcare Facilities & Services

1st Jan change Capi. Investor Rating ESG Refinitiv
-6.74% 11.06B
A-
-12.66% 86.52B
B-
+18.83% 85.39B
C+
+12.75% 29.95B
C+
-10.31% 17.31B
B
-9.33% 15.23B
A-
-6.91% 14.27B
A-
+2.75% 12.23B
A-
-29.82% 11.68B - -
+24.41% 11.44B
B-
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. FME Stock
  4. Ratings Fresenius Medical Care AG